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Introduction 
Amyloidosis is a systemic or organ-
limited disease in which there is 
extracellular deposition of amyloid fibrils 
that gradually replace normal tissue in 
various organs in different pathological 
states, leading to loss of normal tissue 
architecture.1 The extent and location of 
amyloid deposition is directly responsible 
for the degree of cardiac failure.1,2  
Usually 25% of the myocardium is 
replaced by amyloid deposition for 
symptoms to appear with congestive heart 
failure being the most common presentation 
of cardiac amyloidosis. In the clinical 
workup of patients with diastolic heart 
failure and myocardial hypertrophy, cardiac 
amyloidosis is an important differential 
diagnosis. Once congestive heart failure 
occurs, the median survival is less than six 
months in untreated patients, and is the most 
common cause of death.2 
 
Case Report 
A 57-year-old female with a history of 
hypertension, diabetes mellitus, paroxysmal 
atrial fibrillation, morbid obesity, and 
multiple myeloma presented for recurrent 
episodes of shortness of air for the past six 
months. The initial echocardiogram revealed 
normal left ventricular systolic function, 
moderate tricuspid and mitral valve 
regurgitation, severe diastolic dysfunction, 
and a “speckled-like" pattern suggestive of 
possible  amyloid  disease.    She  underwent  
 
 
multiple fat biopsies without any conclusive 
evidence of amyloidosis.   Cardiac MRI also 
was performed and was non-conclusive for 
the diagnosis of cardiac amyloid. 
Meanwhile, she had worsening dyspnea and 
interval increase in her pericardial effusion 
size along with worsening tricuspid and 
mitral valve regurgitation.  
Her physical exam was positive for a 3/6 
systolic murmur at the level of the mitral 
valve radiating to the axillary region and 
bilateral lower extremities edema. Chest x-
ray revealed only mild cardiomegaly. Her 
electrocardiogram obtained at rest is shown 
below in Figure 1. She underwent elective 
pericardiocentesis and pericardial fluid 
analysis revealed only chronic inflammatory 
pattern with modest improvement in her 
symptoms. She was started on diuretic 
therapy with good response and significant 
improvement in her symptoms. She 
underwent a right heart catheterization and a 
right ventricular biopsy revealing a positive 
Congo red staining consistent with cardiac 
amyloidosis. 
 
Discussion 
Cardiac amyloidosis is an invariably 
progressive infiltrative cardiomyopathy that 
carries a grave prognosis. Cardiac 
involvement may be present in up to one-
third of patients with primary amyloidosis 
(designated AL) resulting from plasma cell 
dyscrasias.1,2 Although only 10% of the 
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Figure 1.  ECG revealing normal sinus rhythm with left axis deviation. Note the low voltage 
findings, anterior wall infarct (pseudo-infarct pattern), absent R wave in precordial leads, and 
possible inferior wall infarct. Artifacts noted in lead V6. 
 
patients with multiple myeloma develop 
systemic light-chain amyloid disease, their 
prognosis is very poor, especially in the 
presence of cardiac amyloidosis.3 
Myocardial infiltration tends to be less with 
secondary amyloidosis (designated AA), in 
which the AA protein deposits tend to be 
smaller and more perivascular in location, 
thus less likely to produce myocardial 
dysfunction.2,4 Other forms include familial 
and senile amyloidosis.2  
The term amyloidosis means “starch-
like.” The heart infiltrated with amyloid 
appears tan and waxy and is rubbery in 
consistency. The atria also are enlarged 
significantly. Histologically, amyloid 
deposits can be detected with Congo red or 
Sirius red staining and are present between 
cardiac myocytes.2,5  
There are four overlapping syndromes 
that may occur with cardiovascular 
involvement of amyloidosis, including 
restrictive cardiomyopathy, systolic heart 
failure, orthostatic hypotension, and 
presentation with conduction system 
disease. Most commonly, patients with 
cardiac amyloidosis present with signs of 
congestive    heart   failure   with   preserved  
 
systolic and abnormal diastolic function.2,4  
Cardiomegaly may be present on chest 
roentgenography. The electrocardiogram 
most often reveals low QRS voltage, and 
bundle branch block and abnormal axis are 
also common. A pattern of old anterior 
myocardial infarction may be simulated by 
diminutive or absent R waves in the right 
precordial leads, or by an old inferior 
infarction by inferior Q-waves (pseudo-
infarct pattern).2,6  Amyloid infiltration of 
the atrium predisposes to atrial fibrillation, 
and ventricular arrhythmias are also 
common. Atrioventricular conduction 
defects are common and electro-
physiological testing is usually necessary to 
detect significant intrahisian block. Sinus 
node dysfunction is also common and the 
ECG may show sick sinus syndrome.6 
Echocardiography is quite valuable and 
reveals increased ventricular wall thickness 
with small intracavitary chambers, enlarged 
atria, and a thickened interatrial septum.  
The walls of the ventricles often reveal a 
distinctive appearance with a sparkling and 
granular texture, most likely resulting from 
the amyloid deposition itself. Pericardial 
effusions may be present, but usually do not 
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advance to tamponade. Doppler echo-
cardiography is valuable to evaluate 
diastolic dysfunction, the degree of which 
offers prognostic information.3,6,7 Cardiac 
MRI has a very high sensitivity for the 
detection of cardiac amyloid, and also may 
be valuable in measuring the extent of 
amyloid deposition in the heart, a significant 
prognostic factor.8,9  
The diagnosis of cardiac amyloidosis 
can be ascertained by either:  (1) a positive 
biopsy from a noncardiac tissue in addition 
to sonographic evidence of amyloidosis, 
which includes a mean left ventricular wall 
thickness of greater than 12 mm in the 
absence of other causes of LV hypertrophy, 
or (2) an endomyocardial biopsy illustrating 
amyloid deposition in addition to laboratory 
and clinical evidence of organ involvement. 
In patients with cardiac involvement, 
endomyocardial biopsy is a relatively safe 
procedure in experienced hands with 100% 
sensitivity in diagnosis of cardiac 
amyloidosis. Biopsy specimen from the 
involved organ, such as the heart or from the 
abdominal fat pad, exhibits a red or pink 
color under light microscopy after chemical 
staining with Congo red and a dramatic 
apple-green birefringence under polarized 
light.2,5,6  
Patients with cardiac amyloidosis have 
few treatment options, although there are 
ongoing attempts to modify the severe 
natural history of this disorder.10 
Approaches for patients with AL 
amyloidosis involve chemotherapy with 
alkylating agents alone or in combination 
with autologous bone marrow stem cell 
transplantation and heart transplantation.2,11 
In terms of conventional cardiac 
medications, the use of digitalis glycosides 
requires additional vigilance because 
patients with cardiac amyloidosis have 
increased sensitivity to digitalis 
preparations. Calcium-channel antagonists 
also require caution because their negative 
inotropic effect has the potential to 
exacerbate heart failure. Pacemakers are 
frequently indicated for conduction system 
disturbances, and implantable cardioverter-
defibrillators may be considered. The 
mainstay of symptom relief in volume 
overloaded patients is the judicious use of 
diuretics, which requires very careful 
titration, in combination with rigorous fluid 
restriction.10  
 
Conclusion 
In summary, cardiac amyloidosis is a 
progressively infiltrative cardiomyopathy 
that should be suspected in patients with 
multiple myeloma and worsening dyspnea. 
It carries a poor prognosis even with 
aggressive therapy. A cardiac screening in 
all patients with multiple myeloma should 
include at least an electrocardiogram and 
complete cardiac sonography.  
 
 
References 
1 Gertz MA, Comenzo R, Falk RH, et al.  
Definition of organ involvement and 
treatment response in immunoglobulin 
light chain amyloidosis (AL): A consensus 
opinion from the 10th International 
Symposium on Amyloid and Amyloidosis, 
Tours, France, 18-22 April 2004. Am J 
Hematol 2005; 79(4):319-328. 
 
 
 
 
2 Falk RH.  Diagnosis and management of 
the cardiac amyloidoses. Circulation 2005; 
112(13):2047-2060. 
3
 Dubrey SW, Cha K, Skinner M, LaValley 
M, Falk RH.  Familial and primary (AL) 
cardiac amyloidosis: Echocardio-
graphically similar diseases with distinctly 
different clinical outcomes.  Heart 1997; 
78(1):74-82. 
Kansas Journal of Medicine 2011      An Unusual Cardiac Manifestation  
 
 24
4 Kyle RA, Gertz MA. Primary systemic 
amyloidosis:  Clinical and laboratory 
features in 474 cases.  Semin Hematol 
1995; 32(1):45-59. 
5
 Pellikka PA, Holmes DR Jr, Edwards WD, 
Nishimura RA, Tajik AJ, Kyle RA.   
Endomyocardial biopsy in 30 patients with 
primary amyloidosis and suspected cardiac 
involvement.  Arch Intern Med 1988; 
148(3):662-666. 
6
 Rahman JE, Helou EF, Gelzer-Bell R, et 
al.  Noninvasive diagnosis of biopsy-
proven cardiac amyloidosis.  J Am Coll 
Cardiol 2004; 43(3):410-415. 
7 Devereux RB, Alonso DR, Lutas EM, et 
al.  Echocardiographic assessment of left 
ventricular hypertrophy: Comparison to 
necropsy findings.  Am J Cardiol 1986; 
57(6):450-458. 
8 Vogelsberg H, Mahrholdt H, Deluigi CC, 
et al.  Cardiovascular magnetic resonance 
in clinically suspected cardiac 
amyloidosis: Noninvasive imaging 
compared to endomyocardial biopsy.  J 
Am Coll Cardiol 2008; 51(10): p. 1022-
1030. 
9
 Kusunose K, Yamada H, Iwase T, et al.  
Images in cardiovascular medicine. 
Cardiac magnetic resonance imaging and 
2-dimensional speckle tracking 
echocardiography in secondary cardiac 
amyloidosis.  Circ J 2010; 74(7):1494-
1496. 
10
 Parikh S, de Lemos JA.  Current 
therapeutic strategies in cardiac 
amyloidosis. Curr Treat Options 
Cardiovasc Med 2005; 7(6):443-448. 
11
 Seldin DC, Anderson JJ, Sanchorawala V, 
et al.  Improvement in quality of life of 
patients with AL amyloidosis treated with 
high-dose melphalan and autologous stem 
cell transplantation. Blood 2004; 
104(6):1888-1893. 
 
Keywords:  electrocardiography, multiple 
myeloma, amyloidosis, cardiomyopathies 
